Les résultats étaient similaires dans la population générale et la souspopulation de plus de 70 ans très vulnérable qui prenait souvent de multiples médicaments. CoNCLusioNs : Le traitement de la douleur névropathique réfractaire à l'aide de pansements médicamentés à la lidocaïne 5 % démontre clairement son efficacité et un excellent profil d'innocuité chez les patients atteints de douleurs névropathiques réfractaires.
for the symptomatic relief of neuropathic pain associated with herpes zoster infection; its efficacy in this condition led physicians to propose its use in other types of neuropathic pain (14) (15) (16) . The chosen indications were localized neuropathic pain, and pain in which allodynia predominates and is difficult to relieve.
The purpose of the present investigation was to study clinical practice patterns in the treatment of localized refractory neuropathic pain, for which the 5% lidocaine-medicated plaster represents a new alternative with benefits outweighing risks. This encouraged us to broaden the scope to other etiologies of localized neuropathic pain. Topical treatment in pain centres was analyzed to:
• describe the population and type of neuropathic pain observed; • evaluate the duration, efficacy and safety of treatment; and • specify the concomitant administration of coanalgesic and other antineuropathic drugs that may interfere with comorbidity.
MeThoDs
The present study was a retrospective observational investigation of patients with refractory neuropathic pain who had been treated in pain centres, between 2001 and 2006, with 5% lidocaine-medicated plaster (Versatis, Grünenthal GmbH, Germany). Each self-adhesive plaster measures 10 cm × 14 cm and contains 700 mg (5% w/w) of lidocaine. It is applied to intact, dry, nonirritated skin for a period of no longer than 12 h. When the maximum recommended dose (three plasters) is applied, approximately 3±2% of the total applied lidocaine dose becomes systemically available. This produces a local analgesic effect by the stabilization of neuronal membranes, which is believed to cause downregulation of sodium channels. Inclusion criteria were as follows: male or female older than 18 years of age; consulting a specialized centre for localized neuropathic pain; a history of treatment failure due to insufficient efficacy or poor tolerability of previous therapy; and requiring regular application of 5% lidocaine-medicated plaster. Medical records had to be available, with an initial evaluation and at least one follow-up visit, at which the maximum and minimum pain intensity reached per day had been recorded. Cases with insufficient information to provide an accurate clinical picture or response to treatment were excluded.
A standardized grid was drafted and tested in three centres. This grid comprised the following:
• Demographic details.
• lidocaine-medicated plaster. Data were collected by eight investigators in July 2007. Authorization was granted by the National Ethics Consultative Committee, which is responsible for all hospitals in France, and the French Commission for Data Processing, Data Files and Individual Liberties. The statistical study was primarily descriptive. The Mantel-Haenszel method was used to evaluate the impact of age on the various parameters. Changes from previous therapies and coanalgesics, before and after treatment with the 5% lidocaine-medicated plaster, were evaluated by McNemar's test on both the general population and the subpopulation older than 70 years of age. The analysis was performed using SAS version 9.1.3 (SAS Institute Inc, USA) for Windows (Microsoft Corporation, USA). The quality and the consistency of clinical data were reviewed independently.
ResuLTs

Populations studied
Eleven centres, including one academic hospital and a regional pain network of 10 centres, participated in the study. They represent a population of two million people, and cover both rural and urban areas. Recruitment was evenly distributed among centres. A total of 431 of 467 dossiers of identified patients could be evaluated. The remaining 36 dossiers were excluded because they contained insufficient information about diagnosis or the evaluation of efficacy. Most patients were older than 40 years of age (84.7%) and 25.0% were older than 70 years of age. A total of 58.8% of the study population were women and 41.2% were men (Table 1) . Most patients (58.0%) were unemployed. Similar numbers of patients were referred to the pain centres by general practitioners (49.7%) and by specialists (50.3%), one-half of whom (53.0%) 
etiology of neuropathic pain
Eighty-nine patients (20.6%) had PHN. More than three-quarters of the patients (n=329; 76.3%) experienced other types of peripheral neuropathic pain. Postoperative pain -mainly following orthopedic surgery of the upper and lower limbs, but also visceral or spinal surgery -was present in 325 patients (75.4%) with peripheral neuropathic pain, while 99 patients (23%) had post-traumatic neuropathic pain. Conversely, only 32 cases (7.4%) were related to cancer treatment and there was one case of diabetic peripheral neuropathy. Pain of central origin (13 patients; 3.0%) included the sequelae of strokes and spinal cord lesions, with the 5% lidocaine-medicated plaster applied over a restricted allodynic area (Table 1) .
Clinical characteristics
The time since onset of the initial lesion responsible for the pain was more than one year in 65.6% of cases and more than three years in 35.7% (Table 1 ). The duration of pain was less than one year in 38.3% of patients, from one to three years in 30.2% and more than three years in 31.3%. In patients older than 70 years of age, 62.7% had experienced pain for more than one year. The intensity of pain before the institution of topical treatment ranged from a minimum of 5.2±2.4 to a maximum of 8.2±1.6 on an 11-point NRS (Figure 1 ).
Previous analgesic treatments
Of the total number of patients in the study, 26 
Treatment
The survey revealed that the mean duration of treatment with 5% lidocaine-medicated plaster was less than three months in 42.1% of cases (45.5% in patients older than 70 years of age), between three and 12 months in 36.9%, and more than one year in 21.1% (22.7% in patients older than 70 years of age). The dosage was one plaster daily in 74% of patients (80.7% in patients older than 70 years of age) and two plasters daily in 13.5% of the total population (12.5% in patients older than 70 years of age). At the end of the investigation, 59.6% of the patients continued treatment with 5% lidocaine-medicated plaster. Efficacy was evaluated from the change in pain intensity between the beginning of treatment and the last recorded assessment (corresponding to the end of the survey), as well as changes in medication use (analgesics and coanalgesics for neuropathic pain). There was a statistically significant decrease in mean pain intensity: from 5.2±2.4 to 3.1±2.5 (P<0.001) for the minimum value, and 8.2±1.6 to 5.3±2.6 (P<0.001) for the maximum value (Figure 1) . A maximum improvement in pain intensity of more than two points between the first and last recorded visit was noted in 73.2% of patients. This two-point improvement was noted at the second visit in 65.6% of cases. For 294 completed dossiers, 45.5% of patients had a pain intensity reduction of more than 50%, and 82.2% had a decrease of at least 30% (Table 2 ). Only 7.5% of patients noted no improvement. In the population older than 70 years of age, 54.4% of patients experienced a pain intensity decrease of more than 50%, and 83.8% a decrease of at least 30%; only 11.8% of the patients showed no improvement ( Table 2) .
The reduction in analgesic consumption was statistically significant: 13.2% (P<0.0001) for WHO step I, 23.7% (P<0.0001) for step II and 9.1% (P<0.0001) for step III analgesics ( Table 3 ). The reduction was even greater in the population older than 70 years of age, with a 16.7% benefit for step I (P=0.0011) and 32.4% for step II (P<0.0001), but a moderate and nonsignificant improvement for step III analgesics (4.9%; P=0.37). The reduction was also significant for coanalgesics for neuropathic pain: for tricyclic antidepressants, it was 14.9% (P<0.0001), for antiepileptics 20.8% (P<0.0001) and for serotonin reuptake inhibitors 4.9% (P=0.005). In the population older than 70 years of age, the reduction was significantly greater for tricyclic antidepressants (17.7%; P=0.001) and antiepileptics (25.5%; P<0.0001), but nonsignificant for selective serotonin reuptake inhibitors (2.9%; P=0.32; Table 3 ).
Treatment-related adverse effects were recorded for 39 patients or 9.0% of the population, and were the cause of treatment discontinuation in 3%. The most common effects were erythema (n=19), pruritis (n=11), burns (n=12) and edema (n=4). 
DisCussioN
The present article describes the follow-up of neuropathic pain patients in specialized units. Although retrospective, the study made it possible to assess the value of 5% lidocaine-medicated plaster in patients with neuropathic pain who met precise clinical criteria (diagnosis, etiology and therapy) and represents a preliminary stage before a prospective clinical evaluation. It was performed five years after the first prescriptions for 5% lidocaine-medicated plaster (2001); hence, the late and restricted use of the DN4 questionnaire, which became available in 2005, and the lack of information about some comorbidity parameters more readily identified today, such as depression, anxiety, sleep disorders and other associated conditions. Incomplete identification of sensory deficits or evoked pain has to be regarded in the context of the use of nonstandardized documentation. However, these results provide an opportunity for therapists to improve the management of pain, its evaluation and follow-up by use of more homogeneous dossier content.
Population
The large cohort of 467 patients recruited from an urban and rural population is representative of patients consulting a specialized pain centre for refractory chronic pain conditions. The age, sex and activities of the present population were similar to those investigated during recent epidemiological studies conducted in France and in Europe (1, 2, 20) . Approximately 25% of patients were older than 70 years of age.
Equal numbers of patients were referred by general practitioners and specialists. There may be several reasons for elderly patients mainly being referred by general practitioners, and young people by consultant orthopedists. In the case of young people, for example, one reason may have been the prevalence of localized postsurgical or post-traumatic neuropathic lesions, with an early onset that is responsible for considerable disability and that compromises the short-term outcome and resumption of activity as well as long-established collaborations with the surgical teams.
Neuropathic pain
The main indication for treatment with 5% lidocaine-medicated plaster was peripheral neuropathic pain; only 13 patients with central pain were included because of the very limited painful and allodynic area. The clinical characteristics of patients' neuropathic pain were consistent with the inclusion criteria and the indication for topical treatment -allodynia, burning and electric shock-type pain were reported in most cases. The diagnosis of neuropathic pain was also defined as a DN4 score of greater than 4. This was used by a small number of patients (n=81) because it became available relatively late in the course of the investigation. The score of greater than 4 correlated particularly well with the high incidence of allodynia. The (19, 21) -ie, burning, crushing, electric shock-type pain, etc -were also frequently observed.
Regarding the etiology of neuropathic pain, the incidence of PHN in the population older than 70 years of age was higher, as is classically described (22) . Most patients did not have PHN (only 20.6%), but a localized neuropathic pain syndrome with allodynia. The etiologies most often reported were trauma and surgery, with a clear majority of orthopedic patients. The pain could be mixed (ie, possess both nociceptive and neuropathic components), but in every case it met the criteria for neuropathic pain. This justifies the indication for 5% lidocaine-medicated plasters, which were prescribed against a background of refractory pain (failure or intolerance to previous therapies), ie, the neuropathic pain had the same symptomatic expression pattern as PHN. The lower prevalence of cancer pain in the present observational study group was not consistent with epidemiological or literature data (23) (24) (25) . This can be partly explained by the fact that cancer pain in France is often managed outside of pain centres, and also that mixed pain is not identified sufficiently often in cancer patients. Pain caused by diabetic neuropathy is a peripheral polyneuropathy that is not usually treated with 5% lidocaine-medicated plasters in France, unlike in other European countries (14) .
All patients in the present study had been treated for neuropathic pain with analgesic treatment that was insufficiently effective or poorly tolerated before a complementary topical treatment was prescribed. The number of previous therapies was high (two to five in three-quarters of the patients).
efficacy
The decrease in NRS scores from the initial high levels (5 to 8; due to the failure of previous treatment) showed that the reduction in pain intensity was statistically and clinically significant for both the minimum and the maximum values. The high percentage (73.2%) of patients relieved by more than two NRS points corroborated the significance of this treatment effect (26) . The efficacy evaluation at one month was predictive of efficacy (68%) at following visits, and justified the therapeutic testing routinely performed in clinical practice, ie, a test after one month of treatment to consider whether it should continue.
Efficacy was also confirmed by the high 30% and 50% responder rates. The significance of these values has been accepted in many studies (27) . These results are particularly satisfactory because treatment had failed in the selected population.
A reduction in drug consumption was observed in all population samples and especially in the elderly, high-risk -often polymedicated -population. The benefit was particularly high for step II analgesics and the population older than 70 years of age, with its well-documented risks of adverse drug reactions and iatrogenic problems (28, 29) . There was also a significant reduction in the consumption of coanalgesics for neuropathic pain such as antidepressants, antiepileptics and psychotropics. Although these agents have a relatively satisfactory number needed to treat in these complex therapeutic situations, they often give rise to severe adverse effects (number needed to harm) (30, 31) and poor compliance, particularly in the elderly population (32) .
Tolerability was good; only minor adverse reactions were related to the use of 5% lidocaine-medicated plaster, similar to results reported in the literature. The mean duration of treatment, performed at a given time in patients who had received this therapy during the five-year inclusion period, was difficult to analyze by retrospective analysis.
The mean dose used of approximately one plaster/day was very similar to doses reported in the literature (9, 14) , and demonstrates an economic advantage compared with the average cost of the other medicinal products proposed (33) . The results suggest that this plaster provides benefit by reducing the prescription of other analgesics and Step II -23.7 <0.0001 -32.4 <0.0001
Step III -9.1 <0.0001 -4.9 0.37 P values correspond to McNemar test. All analgesic treatments were administered alone or in combination. SSRI Selective serotonin reuptake inhibitor reducing morbidity; many of the prescriptions authorized by health authorities within the scope of the named-patient program were justified because of major adverse reactions. This is particularly true of the high-risk elderly population and in those with impaired vital functions (renal, hepatic, cardiovascular insufficiency, etc) (34) .
CoNCLusioN
The present retrospective study investigated a large population of patients, diverse in terms of age, place of residence, profession and patient care pathway, who were suffering from refractory, chronic neuropathic pain and had been referred to a specialized pain centre.
From an epidemiological standpoint, the patients who benefitted most from therapy with 5% lidocaine-medicated plaster were those who presented with postsurgical and/or post-traumatic localized neuropathic pain, in whom more usual therapies provided inadequate pain relief or produced adverse reactions. Observational study of our clinical practices analyzed the value of this therapy, which has been recommended as a first-line treatment by certain expert groups (4, 27) as part of our treatment armamentarium for localized neuropathic pain. We were able to conduct a de facto analysis of the clinical impression during empirical use of this topical treatment. The results clearly demonstrate efficacy and an excellent safety profile with very few local adverse reactions, as well as a simplification of treatment patterns and a reduction in concomitant medication. The next step is to confirm these results for different etiologies in complementary prospective studies and to demonstrate a good benefit-risk ratio in specific populations.
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